Sepsis

The FDA has approved insulin icodec-abae as the first once-weekly basal insulin option for glycemic control in adults with type 2 diabetes.

The FDA has approved insulin icodec-abae as the first once-weekly basal insulin option for glycemic control in adults with type 2 diabetes.

The FDA has approved insulin icodec-abae as the first once-weekly basal insulin option for glycemic control in adults with type 2 diabetes.

The FDA has approved insulin icodec-abae as the first once-weekly basal insulin option for glycemic control in adults with type 2 diabetes.

The FDA has approved insulin icodec-abae as the first once-weekly basal insulin option for glycemic control in adults with type 2 diabetes.

The FDA has approved Avlayah (tividenofusp alfa-eknm) for certain pediatric patients with Hunter syndrome, marking the first approval targeting the disease's neurologic complications and offering clinicians...

The FDA has approved Avlayah (tividenofusp alfa-eknm) for certain pediatric patients with Hunter syndrome, marking the first approval targeting the disease's neurologic complications and offering clinicians...

The FDA has approved Avlayah (tividenofusp alfa-eknm) for certain pediatric patients with Hunter syndrome, marking the first approval targeting the disease's neurologic complications and offering clinicians...

The FDA has approved Opdivo (nivolumab) in combination with doxorubicin, vinblastine, and dacarbazine for adults and pediatric patients aged 12 years and older with previously untreated stage III or IV...

The FDA has approved Opdivo (nivolumab) in combination with doxorubicin, vinblastine, and dacarbazine for adults and pediatric patients aged 12 years and older with previously untreated stage III or IV...